Emergency Medicine
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
Excellent review of thrombosis and anticoagulation in #COVID19 by @connors_md and @RMKGandhi
Paradoxically, anticoagulation may be most beneficial in moderately ill patients with #COVID19, as the bleeding risk may be excessive in the critically ill https://t.co/75TiNs0iej pic.twitter.com/v0avzhFl3f
— John Ross (@JohnRossMD) February 6, 2021
Small RCT: Peginterferon lambda increases viral clearance in outpatients with COVID-19
9 Feb, 2021 | 01:36h | UTC
Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy
7 Feb, 2021 | 20:55h | UTCManagement of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)
Audio Clinical Review: Management of Immunotherapy-Related Toxicities
Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities
Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack
7 Feb, 2021 | 20:54h | UTCSee calculator: Canadian TIA Score
Commentary on Twitter
Jeff Perry is at it again! The ABCD2 score lacks the ability to discriminate low and high risk patients following TIA, so Perry et al. have validated the Canadian TIA Score.
Infographic and bedside calculator: https://t.co/OcbaK1aG3t
Full publication: https://t.co/wt87PKzNkO pic.twitter.com/q3QdgVxp6x
— EM Ottawa (@emergmedottawa) February 4, 2021
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension
4 Feb, 2021 | 01:18h | UTC
Commentary on Twitter
Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?
Maybe or maybe not
But this trial slow to cool, not very cool, underpowered and mod rate of dropout
Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e
— Graham Nichol (@grahamnichol) January 29, 2021
German 2021 guideline update on acute therapy and management of anaphylaxis
4 Feb, 2021 | 01:17h | UTC
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
4 Feb, 2021 | 01:39h | UTCInvited Commentary: Azithromycin, RECOVERY, and the power of large, simple trials – The Lancet
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial